CoChat

Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation

Open access
Bayraktar, Ulas D., Bashir, Qaiser, Qazilbash, Muzaffar, Champlin, Richard E., Ciurea, Stefan O. · 2013 · Biology of Blood and Marrow Transplantation
Cited by 119

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

a b s t r a c tMelphalan remains the most widely used agent in preparative regimens for hematopoietic stem cell transplantation (SCT).From its initial discovery more than 50 years ago, it has been gradually incorporated in the conditioning regimens for both autologous and allogeneic transplantations because of its myeloablative properties and broad antitumor effects as a DNA alkylating agent.Melphalan remains the mainstay conditioning for multiple myeloma and lymphomas, and it has been used successfully in preparative regimens of a variety of other hematological and nonhematological malignancies.The addition of newer agents to conditioning, such as bortezomib or lenalidomide for myeloma or clofarabine for myeloid malignancies, may improve antitumor effects for transplantation, whereas melphalan in combination with alemtuzumab may represent a backbone for future cellular therapy because of reliable engraftment and low toxicity profile.This review summarizes the development and the current use of this remarkable drug in hematopoietic SCT.Ó 2013 American Society for Blood and Marrow Transplantation. MMMyeloma has been the most common indication for melphalan conditioning in transplantation.Despite the advent of novel myeloma agents, MM remains an incurable disease, and ASCT is generally recommended for all eligible American Society for Blood ASBMT and Marrow

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbmt.2012.08.011

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 119

Metadata

Authors
Bayraktar, U. D., Bashir, Q., Qazilbash, M., Champlin, R. E., & Ciurea, S. O.
Venue
Biology of Blood and Marrow Transplantation
Publisher
Elsevier BV
Published
2013-03
Volume
19
Issue
3
Pages
344-356
ISSN
1083-8791 (ISSN-L)
OpenAlex
W2044225326
Cited by
119
References
6
FWCI
4.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. https://app.cochat.ai/papers/10.1016/j.bbmt.2012.08.011
The paper
Bayraktar, U. D., Bashir, Q., Qazilbash, M., Champlin, R. E., & Ciurea, S. O. (2013). Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2012.08.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.